Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Sweeney

Showing results (51-60 of 88) with videos related to

Pageof 9
Sort By:
European Urology Oncology|August 9, 2023
Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate CancerPhilip Sutera, Amol C Shetty, Yang Song, et al.
European Urology|January 30, 2025
Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 TrialJohann S de Bono, Meng He, Zhen Shi, et al.
Urology|December 29, 2020
Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting SummaryMartin R Hofmann, Maha Hussain, Scott M Dehm, et al.
Journal of Thrombosis and Haemostasis : JTH|July 20, 2019
Temporal map of the pig polytrauma plasma proteome with fluid resuscitation and intravenous vitamin C treatmentEmmanuel K Cudjoe, Zaneera H Hassan, Le Kang, et al.
Drug Development Research|July 14, 2019
Dimethylaminoparthenolide reduces the incidence of dysplasia and ameliorates a wasting syndrome in HPV16-transgenic miceJoana M O Santos, Alexandra Moreira-Pais, Tiago Neto, et al.
JAMA Oncology|March 2, 2023
First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysisIrbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, Huan He, et al.
European Urology Focus|February 19, 2026
Stratifying Risk and Treatment Benefit: A Model Predicting Overall Survival in Men with Metastatic De Novo Hormone-sensitive Prostate Cancer in Trials Investigating Docetaxel (the STOPCAP Collaboration)Susan Halabi, Bin Luo, Chenxi Yu, et al.
The Lancet. Oncology|March 13, 2019
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket studyFunda Meric-Bernstam, Herbert Hurwitz, Kanwal Pratap Singh Raghav, et al.
Investigational New Drugs|November 15, 2011
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combinationMichael Millward, Timothy Price, Amanda Townsend, et al.
The Oncologist|November 30, 2017
Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access ProgramOliver Sartor, Nicholas J Vogelzang, Christopher Sweeney, et al.
Pageof 9

Showing results (51-60 of 88) with videos related to

Sort By:
Pageof 9
European Urology Oncology|August 9, 2023
Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate CancerPhilip Sutera, Amol C Shetty, Yang Song, et al.
European Urology|January 30, 2025
Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 TrialJohann S de Bono, Meng He, Zhen Shi, et al.
Urology|December 29, 2020
Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting SummaryMartin R Hofmann, Maha Hussain, Scott M Dehm, et al.
Journal of Thrombosis and Haemostasis : JTH|July 20, 2019
Temporal map of the pig polytrauma plasma proteome with fluid resuscitation and intravenous vitamin C treatmentEmmanuel K Cudjoe, Zaneera H Hassan, Le Kang, et al.
Drug Development Research|July 14, 2019
Dimethylaminoparthenolide reduces the incidence of dysplasia and ameliorates a wasting syndrome in HPV16-transgenic miceJoana M O Santos, Alexandra Moreira-Pais, Tiago Neto, et al.
JAMA Oncology|March 2, 2023
First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysisIrbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, Huan He, et al.
European Urology Focus|February 19, 2026
Stratifying Risk and Treatment Benefit: A Model Predicting Overall Survival in Men with Metastatic De Novo Hormone-sensitive Prostate Cancer in Trials Investigating Docetaxel (the STOPCAP Collaboration)Susan Halabi, Bin Luo, Chenxi Yu, et al.
The Lancet. Oncology|March 13, 2019
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket studyFunda Meric-Bernstam, Herbert Hurwitz, Kanwal Pratap Singh Raghav, et al.
Investigational New Drugs|November 15, 2011
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combinationMichael Millward, Timothy Price, Amanda Townsend, et al.
The Oncologist|November 30, 2017
Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access ProgramOliver Sartor, Nicholas J Vogelzang, Christopher Sweeney, et al.
Pageof 9